{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:50:25Z","timestamp":1792090225639,"version":"4.4.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01611-x","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:02:30Z","timestamp":1792087350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Resistance Phenotypes and Treatment Sequencing After Immune Checkpoint Blockade in MSI-H\/dMMR Metastatic Colorectal Cancer: A Review"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1611_CR1","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1500596.","journal-title":"N Engl J Med"},{"key":"1611_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733.","journal-title":"Science"},{"key":"1611_CR3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(17)30422-9.","journal-title":"Lancet Oncol"},{"key":"1611_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773\u20139. https:\/\/doi.org\/10.1200\/JCO.2017.76.9901.","journal-title":"J Clin Oncol"},{"key":"1611_CR5","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","volume":"33","author":"T Andr\u00e9","year":"2022","unstructured":"Andr\u00e9 T, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022;33:1052\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2022.06.008.","journal-title":"Ann Oncol"},{"key":"1611_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz HJ, Van Cutsem E, Limon ML, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40:161\u201370. https:\/\/doi.org\/10.1200\/JCO.21.01015.","journal-title":"J Clin Oncol"},{"key":"1611_CR7","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med"},{"key":"1611_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(22)00197-8.","journal-title":"Lancet Oncol"},{"key":"1611_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","volume":"36","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36:277\u201384. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.012.","journal-title":"Ann Oncol"},{"key":"1611_CR10","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andr\u00e9","year":"2024","unstructured":"Andr\u00e9 T, Elez E, Van Cutsem E, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024;391:2014\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2402141.","journal-title":"N Engl J Med"},{"key":"1611_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405:383\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(24)02848-4.","journal-title":"Lancet"},{"key":"1611_CR12","doi-asserted-by":"publisher","first-page":"116119","DOI":"10.1016\/j.ejca.2025.116119","volume":"232","author":"B Cervantes","year":"2026","unstructured":"Cervantes B, Grosnon C, Samaille T, et al. Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): different entities requiring tailored management. Eur J Cancer. 2026;232:116119. https:\/\/doi.org\/10.1016\/j.ejca.2025.116119.","journal-title":"Eur J Cancer"},{"key":"1611_CR13","doi-asserted-by":"publisher","first-page":"oyag235","DOI":"10.1093\/oncolo\/oyag235","volume":"31","author":"M LaPelusa","year":"2026","unstructured":"LaPelusa M, Shah P, Bhamidipati D, et al. Patterns of progression and survival in patients with mismatch repair deficient\/microsatellite instability-high metastatic colorectal cancer treated with immunotherapy. Oncologist. 2026;31:oyag235. https:\/\/doi.org\/10.1093\/oncolo\/oyag235.","journal-title":"Oncologist"},{"key":"1611_CR14","doi-asserted-by":"publisher","first-page":"115645","DOI":"10.1016\/j.ejca.2025.115645","volume":"227","author":"C Gallois","year":"2025","unstructured":"Gallois C, Ambrosini M, Lonardi S, et al. Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Eur J Cancer. 2025;227:115645. https:\/\/doi.org\/10.1016\/j.ejca.2025.115645.","journal-title":"Eur J Cancer"},{"key":"1611_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"key":"1611_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, V\u00e9tizou M, Daill\u00e8re R, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44:1255\u201369. https:\/\/doi.org\/10.1016\/j.immuni.2016.06.001.","journal-title":"Immunity"},{"key":"1611_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jamaoncol.2018.4942","volume":"5","author":"R Cohen","year":"2019","unstructured":"Cohen R, Hain E, Buhard O, et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol. 2019;5:551\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4942.","journal-title":"JAMA Oncol"},{"key":"1611_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41416-023-02524-3","volume":"130","author":"C Flecchia","year":"2024","unstructured":"Flecchia C, Auclin E, Alouani E, et al. Primary resistance to immunotherapy in patients with a dMMR\/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study. Br J Cancer. 2024;130:442\u20139. https:\/\/doi.org\/10.1038\/s41416-023-02524-3.","journal-title":"Br J Cancer"},{"key":"1611_CR19","doi-asserted-by":"publisher","first-page":"e001499","DOI":"10.1136\/jitc-2020-001499","volume":"8","author":"R Cohen","year":"2020","unstructured":"Cohen R, Bennouna J, Meurisse A, et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J Immunother Cancer. 2020;8:e001499. https:\/\/doi.org\/10.1136\/jitc-2020-001499.","journal-title":"J Immunother Cancer"},{"key":"1611_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2020.11.009","volume":"144","author":"R Colle","year":"2021","unstructured":"Colle R, Radzik A, Cohen R, et al. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer. 2021;144:9\u201316. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.009.","journal-title":"Eur J Cancer"},{"key":"1611_CR21","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.5858\/arpa.2021-0632-CP","volume":"146","author":"AN Bartley","year":"2022","unstructured":"Bartley AN, Mills AM, Konnick E, et al. Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American Pathologists in collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med. 2022;146:1194\u2013210. https:\/\/doi.org\/10.5858\/arpa.2021-0632-CP.","journal-title":"Arch Pathol Lab Med"},{"key":"1611_CR22","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1200\/JCO.22.02462","volume":"41","author":"P Vikas","year":"2023","unstructured":"Vikas P, Messersmith H, Compton C, et al. Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline. J Clin Oncol. 2023;41:1943\u20138. https:\/\/doi.org\/10.1200\/JCO.22.02462.","journal-title":"J Clin Oncol"},{"key":"1611_CR23","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","volume":"30","author":"C Luchini","year":"2019","unstructured":"Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30:1232\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdz116.","journal-title":"Ann Oncol"},{"key":"1611_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"},{"key":"1611_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.2016.71.9807","volume":"35","author":"AR Sepulveda","year":"2017","unstructured":"Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Clin Oncol. 2017;35:1453\u201386. https:\/\/doi.org\/10.1200\/JCO.2016.71.9807.","journal-title":"J Clin Oncol"},{"key":"1611_CR26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/cas.16039","volume":"115","author":"H Bando","year":"2024","unstructured":"Bando H, Yamaguchi K, Mitani S, et al. Japanese Society of Medical Oncology clinical guidelines: molecular testing for colorectal cancer treatment, 5th edition. Cancer Sci. 2024;115:1014\u201321. https:\/\/doi.org\/10.1111\/cas.16039.","journal-title":"Cancer Sci"},{"key":"1611_CR27","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"key":"1611_CR28","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1093\/oncolo\/oyae249","volume":"29","author":"M Fakih","year":"2024","unstructured":"Fakih M, Sandhu J, Li X, Wang C. Liver metastases and peritoneal metastases and response to checkpoint inhibitors in metastatic colorectal cancer with microsatellite instability. Oncologist. 2024;29:1052\u20138. https:\/\/doi.org\/10.1093\/oncolo\/oyae249.","journal-title":"Oncologist"},{"key":"1611_CR29","doi-asserted-by":"publisher","first-page":"e004001","DOI":"10.1136\/jitc-2021-004001","volume":"10","author":"G Fuc\u00e0","year":"2022","unstructured":"Fuc\u00e0 G, Cohen R, Lonardi S, et al. Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer. 2022;10:e004001. https:\/\/doi.org\/10.1136\/jitc-2021-004001.","journal-title":"J Immunother Cancer"},{"key":"1611_CR30","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","volume":"25","author":"AR Parikh","year":"2019","unstructured":"Parikh AR, Leshchiner I, Elagina L, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25:1415\u201321. https:\/\/doi.org\/10.1038\/s41591-019-0561-9.","journal-title":"Nat Med"},{"key":"1611_CR31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1200\/PO.21.00101","volume":"5","author":"F Loupakis","year":"2021","unstructured":"Loupakis F, Sharma S, Derouazi M, et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. JCO Precis Oncol. 2021;5:1166\u201377. https:\/\/doi.org\/10.1200\/PO.21.00101.","journal-title":"JCO Precis Oncol"},{"key":"1611_CR32","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30:3272\u201383. https:\/\/doi.org\/10.1038\/s41591-024-03254-6.","journal-title":"Nat Med"},{"key":"1611_CR33","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2326-6066.CIR-18-0683","volume":"7","author":"C Gurjao","year":"2019","unstructured":"Gurjao C, Liu D, Hofree M, et al. Intrinsic resistance to immune checkpoint blockade in a mismatch repair-deficient colorectal cancer. Cancer Immunol Res. 2019;7:1230\u20136. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0683.","journal-title":"Cancer Immunol Res"},{"key":"1611_CR34","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","volume":"55","author":"PMK Westcott","year":"2023","unstructured":"Westcott PMK, Muyas F, Hauck H, et al. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nat Genet. 2023;55:1686\u201395. https:\/\/doi.org\/10.1038\/s41588-023-01499-4.","journal-title":"Nat Genet"},{"key":"1611_CR35","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184:596\u2013e61414. https:\/\/doi.org\/10.1016\/j.cell.2021.01.002.","journal-title":"Cell"},{"key":"1611_CR36","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463\u20139. https:\/\/doi.org\/10.1126\/science.aaf1490.","journal-title":"Science"},{"key":"1611_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000417","volume":"45","author":"C Zhang","year":"2022","unstructured":"Zhang C, Li D, Xiao B, et al. B2M and JAK1\/2-mutated MSI-H colorectal carcinomas can benefit from anti-PD-1 therapy. J Immunother. 2022;45:187\u201393. https:\/\/doi.org\/10.1097\/CJI.0000000000000417.","journal-title":"J Immunother"},{"key":"1611_CR38","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u201343. https:\/\/doi.org\/10.1038\/nature25492.","journal-title":"Nature"},{"key":"1611_CR39","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"key":"1611_CR40","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","volume":"30","author":"AB Schrock","year":"2019","unstructured":"Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30:1096\u2013103. https:\/\/doi.org\/10.1093\/annonc\/mdz134.","journal-title":"Ann Oncol"},{"key":"1611_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejca.2023.03.029","volume":"187","author":"P Manca","year":"2023","unstructured":"Manca P, Corti F, Intini R, et al. Tumour mutational burden as a biomarker in patients with mismatch repair deficient\/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Eur J Cancer. 2023;187:15\u201324. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.029.","journal-title":"Eur J Cancer"},{"key":"1611_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/ijms24010118","volume":"24","author":"E \u00c9lez","year":"2023","unstructured":"\u00c9lez E, Mulet-Margalef N, Sanso M, et al. A comprehensive biomarker analysis of microsatellite unstable\/mismatch repair deficient colorectal cancer cohort treated with immunotherapy. Int J Mol Sci. 2023;24:118. https:\/\/doi.org\/10.3390\/ijms24010118.","journal-title":"Int J Mol Sci"},{"key":"1611_CR43","doi-asserted-by":"publisher","first-page":"114290","DOI":"10.1016\/j.ejca.2024.114290","volume":"210","author":"M Ambrosini","year":"2024","unstructured":"Ambrosini M, Tougeron D, Modest D, et al. BRAF\u2009+\u2009EGFR\u2009\u00b1\u2009MEK inhibitors after immune checkpoint inhibitors in BRAF V600E-mutated and deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer. Eur J Cancer. 2024;210:114290. https:\/\/doi.org\/10.1016\/j.ejca.2024.114290.","journal-title":"Eur J Cancer"},{"key":"1611_CR44","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/cancers14020406","volume":"14","author":"QL Bui","year":"2022","unstructured":"Bui QL, Mas L, Hollebecque A, et al. Treatments after immune checkpoint inhibitors in patients with dMMR\/MSI metastatic colorectal cancer. Cancers (Basel). 2022;14:406. https:\/\/doi.org\/10.3390\/cancers14020406.","journal-title":"Cancers (Basel)"},{"key":"1611_CR45","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381:1632\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1908075.","journal-title":"N Engl J Med"},{"key":"1611_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39:273\u201384. https:\/\/doi.org\/10.1200\/JCO.20.02088.","journal-title":"J Clin Oncol"},{"key":"1611_CR47","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","volume":"392","author":"E Elez","year":"2025","unstructured":"Elez E, Yoshino T, Shen L, et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer. N Engl J Med. 2025;392:2425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2501912.","journal-title":"N Engl J Med"},{"key":"1611_CR48","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR-directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713\u201329. https:\/\/doi.org\/10.1093\/annonc\/mdx175.","journal-title":"Ann Oncol"},{"key":"1611_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","volume":"24","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24:496\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(23)00150-X.","journal-title":"Lancet Oncol"},{"key":"1611_CR50","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","volume":"22","author":"S Siena","year":"2021","unstructured":"Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(21)00086-3.","journal-title":"Lancet Oncol"},{"key":"1611_CR51","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","volume":"25","author":"K Raghav","year":"2024","unstructured":"Raghav K, Siena S, Takashima A, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:1147\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00380-2.","journal-title":"Lancet Oncol"},{"key":"1611_CR52","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1714448.","journal-title":"N Engl J Med"},{"key":"1611_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(19)30856-3.","journal-title":"Lancet Oncol"},{"key":"1611_CR54","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/0008-5472.CAN-18-3126","volume":"79","author":"E Cocco","year":"2019","unstructured":"Cocco E, Benhamida J, Middha S, et al. Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF\/KRAS are enriched for targetable kinase fusions. Cancer Res. 2019;79:1047\u201353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3126.","journal-title":"Cancer Res"},{"key":"1611_CR55","doi-asserted-by":"publisher","first-page":"100084","DOI":"10.1016\/j.esmogo.2024.100084","volume":"5","author":"M Svrcek","year":"2024","unstructured":"Svrcek M, Cayre A, Samaille T, et al. High prevalence of NTRK fusions in sporadic dMMR\/MSI mCRC RAS\/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy. ESMO Gastrointest Oncol. 2024;5:100084. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100084.","journal-title":"ESMO Gastrointest Oncol"},{"key":"1611_CR56","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:497\u2013507. https:\/\/doi.org\/10.1016\/S1470-2045(19)30862-9.","journal-title":"Lancet Oncol"},{"key":"1611_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388:44\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2212419.","journal-title":"N Engl J Med"},{"key":"1611_CR58","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;389:2125\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2308795.","journal-title":"N Engl J Med"},{"key":"1611_CR59","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388:1657\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2214963.","journal-title":"N Engl J Med"},{"key":"1611_CR60","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402:41\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(23)00772-9.","journal-title":"Lancet"},{"key":"1611_CR61","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X.","journal-title":"Lancet"},{"key":"1611_CR62","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.clcc.2020.02.006","volume":"19","author":"S Das","year":"2020","unstructured":"Das S, Allen A, Berlin J. Immunotherapy after immunotherapy: response rescue in a patient with microsatellite instability-high colorectal cancer post-pembrolizumab. Clin Colorectal Cancer. 2020;19:137\u201340. https:\/\/doi.org\/10.1016\/j.clcc.2020.02.006.","journal-title":"Clin Colorectal Cancer"},{"key":"1611_CR63","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1634\/theoncologist.2018-0686","volume":"24","author":"A Winer","year":"2019","unstructured":"Winer A, Ghatalia P, Bubes N, et al. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1\/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with Lynch syndrome, metastatic colon, and localized urothelial cancer. Oncologist. 2019;24:1416\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2018-0686.","journal-title":"Oncologist"},{"key":"1611_CR64","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 2019;5:1310\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022.","journal-title":"JAMA Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01611-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:02:31Z","timestamp":1792087351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01611-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01611-x","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"19 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"239"}}